Table 1.
Characteristics at inclusion and during follow-up (n = 1013)
| Inclusion | |
| Age; years, median (IQR) | 35 (30–42) |
| Sex; female, n (%) | 808 (79.8) |
| WHO clinical stage 1 or 2; n (%) | 912 (90) |
| CD4 cells/mm3 | |
| Median (IQR) | 465 (379–578) |
| Categories, n (%) | |
| < 350 | 197 (19.4) |
| 350–499 | 392 (38.7) |
| ≥ 500 | 424 (41.9) |
| Plasma HIV-1 RNA; log10 copies/ml* | |
| Median (IQR) | 4.7 (4.0–5.3) |
| Categories; n (%) | |
| < 5 | 652 (64.6) |
| ≥ 5 | 358 (35.4) |
| PBMC HIV-1 DNA; log10 copies/106 cells | |
| Median (IQR) | 2.9 (2.5–3.2) |
| Categories; n (%) | |
| < 3 | 576 (56.9) |
| ≥ 3 | 437 (43.1) |
| 1st line ART regimen; n (%) | |
| TDF/FTC plus EFV | 700 (69.1) |
| TDF/FTC plus LPV/r | 235 (23.2) |
| TDF/FTC plus AZT | 78 (7.7) |
| Follow-up | |
| Duration of follow-up; patient years | 2376 |
| Lost to follow-up; n (%) | 30 (3.0) |
| Death; n (%) | 21 (2.1) |
| CD4 count at M30; cells/mm3# | |
| Median (IQR) | 717 (548–887) |
| Categories; n (%) | |
| < 350 | 39 (4.6) |
| 350–499 | 119 (14.0) |
| ≥ 500 | 693 (81.4) |
| Plasma HIV-1 RNA at M30; log10 copies/ml¤ | |
| Median (IQR) | 0 (0–3.49) |
| Categories; n (%) | |
| < 100 | 711 (83.9) |
| 100–999 | 29 (3.4) |
| 1000–9999 | 42 (5.0) |
| 10.000–99.999 | 32 (3.8) |
| ≥ 100.000 | 33 (3.9) |
IQR interquartile range; WHO World Health Organization; ART antiretroviral treatment; TDF tenofovir; FTC emtricitabine; AZT azidothymidine; LPV/r lopinavir/ritonavir; DNA desoxyribonucleic acid; RNA ribonucleic acid; n number of patients
*n = 1010 (3 missing values)
¤n = 847
#n = 851